We are in the era of controlled release formulations, but new emerging technologies are coming, such as fixed dose combinations or those with dual release profile
The ENVI Committee’s adoption of the Compromise Amendments on the SPC manufacturing waiver proposed regulation make genericists happy and originator disappointed.
A sample of Italian workers have been involved in the research "Talents in the Life Science 2018" of Kelly Services, according to which about two thirds (67%) of the respondents work with contractual forms different from the permanent one
Shift the focus from cost to value. An analisys of medical device markets and industry direction of next years, till 2030.
The digital integration of different single control systems operating within a production environment is a key feature of the new paradigm of Industry 4.0 manufacturing. Dos & Donts developed the Hazel® platform to support the needs of the pharmaceutical industry of a better integration and communication of systems, especially to control the strictly regulated cleanroom environment
The new IT platform launched by the European Medicines Agency is based on the Iris Regulatory & Scientific Information Management Platform, to directly and safely manage notifications of medicinal products intended for parallel distribution
The main producers are adapting to new green economy requirements and the packaging of pharmaceutical products are made using recyclable materials such us plastic, paper, glass and aluminum
Falsified medicines are often disguised as authentic medicines but may contain ingredients of bad or toxic quality, or in the wrong dosage. As they have not been properly checked for quality, safety and efficacy, as required by strict EU authorisation, they can pose a real risk to your health
The potential of blockchain technology in the pharmaceutical logistics industry is significant; however, the transition to the effective adoption of these new solutions will require further technological development and the willingness to collaborate on the part of all the actors involved
Next generation biotech could allow 200 years to live in the coming years. Based on Kris Verburgh, medical doctor interested in preventative medicine and aging and author of The Longevity Code "In the near future, we will see a new biotech age unfolding, in which our health, bodies and lifespan will drastically change"